Hormonal
Activation of PPAR-alpha using agonists like fenofibrate or fish oil reduces hepatic steatosis and insulin resistance in NAFLD by upregulating mitochondrial beta-oxidation and reducing de novo lipogenesis.
If you have fatty liver, focusing on weight loss and exercise is the most effective first step. Pharmacological interventions targeting PPAR-alpha (like fenofibrate) can help reduce liver fat and improve insulin sensitivity by boosting fat burning in the liver, but they are adjunctive to lifestyle changes.
Targeting PPAR-alpha has been proved a promising therapeutic approach to control NAFLD through the upregulation of beta-oxidation genes and the inhibition of DNL and gluconeogenesis enzymes.
Why this rating
Evidence is derived from murine models and some human trials (FLIRT, etc.), but the paper is a review/editorial summarizing various studies rather than a single large RCT.
Source
Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease
Vanessa Souza‐Mello · World Journal of Hepatology · 2015
DOI 10.4254/wjh.v7.i8.1012
More from this paper
- High intake of simple carbohydrates (sucrose, fructose) and high-fat diets disrupt PPAR-alpha and PPAR-gamma balance, leading to reduced beta-oxidation and increased lipogenesis, which drives NAFLD progression.Good
- Total activation of PPAR-gamma (e.g., via rosiglitazone) can be detrimental to liver histology by promoting hepatic lipogenesis, whereas partial activation (e.g., via telmisartan or pioglitazone) improves insulin sensitivity and reduces steatosis without the harmful lipid accumulation.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →